Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 351

Sort by

Sort Order Select

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Blood (2025) 146 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2025-3733

Published: 2025

Journal Articles

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Roch Houot, Pablo Arija, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Cedric Portugues, Catherine Thieblemont, Markqayne Ray, Yin Yang, Sante Cundari, Camille Linot, Divyesh Mistry, Martijn Simons, Anna Gittfried, François Lemonnier

Blood (2025) 146 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2025-3714

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

Prognostic value of baseline metabolic tumor volume from lysa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma

Jules Zhang-Yin, Anne Ségolène Cottereau, Romain Ould-Ammar, Loïc Chartier, Romain Ricci, Catherine Thieblemont, David Sibon, Olivier Casasnovas, Loic Ysebaert, Gandhi Damaj, Stephanie Guidez, Gian Matteo Pica, Marc Andre, Philippe Gaulard, Marie-Helene Delfau-Larue, Franck Morschhauser, Richard Delarue, Vincent Camus, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 894.

https://doi.org/10.1182/blood-2025-894

Published: 2025

Journal Articles

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Shruti Sridhar, Will Harris, Chartsiam Tipgomut, Qiang Pan-Hammarstrom, Gilles Salles, Alex Herrera, Marek Trneny, Franck Morschhauser, Connie Lee Batlevi, Matthew Sugidono, Yanwen Jiang, Georg Lenz, Anand Devaprasath Jeyasekharan

Blood (2025) 146 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2025-3522

Published: 2025

Journal Articles

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

Eliza Hawkes, Clementine Sarkozy, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Alex Herrera, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena Perna, Charalambos Andreadis

Blood (2025) 146 (Supplement 1): 3615.

https://doi.org/10.1182/blood-2025-3615

Published: 2025

Journal Articles

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood (2025) 146 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2025-3614

Published: 2025

Journal Articles

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Blood (2025) 146 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2025-5923

Published: 2025

Journal Articles

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Gabriel Brisou, Roch Houot, Roberta Di Blasi, Guillaume Cartron, Franck Morschhauser, Emmanuel Bachy, Cristina Castilla-Llorente, Axel André, Michael Loschi, François-Xavier Gros, Pierre Bories, Blandine Guffroy, Eve Gehlkopf, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2025-4541

Published: 2025

Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 682.

https://doi.org/10.1182/blood-2025-682

Published: 2025

Journal Articles

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Stephanie Guidez, Marie-Thérèse Rubio, Roberta Di Blasi, Gabriel Brisou, Morgane Cheminant, Emmanuel Bachy, Franck Morschhauser, Cristina Castilla-Llorente, Blandine Guffroy, Roch Houot, Steven Le Gouill, Olivier Hermine, Fabien Le Bras, Laure Ricard, Damien Roos Weil

Blood (2025) 146 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2025-3598

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 5329.

https://doi.org/10.1182/blood-2025-5329

Published: 2025

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Prognostic value of baseline metabolic tumor volume from lysa ro-CHOP trial inpatients with previously untreated peripheral T-cell lymphoma

A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only